IntroductIon
There are several types of dermatitis or skin inflammation, but the most serious are those characteristic of allergen-driven atopic eczema and scleroderma. These diseases have several commonalities, not least of which is excessive keratinocyte activity. This results in the production of a range of inflammatory mediators that control the recruitment and cross talk with the immune system, and keratinocytes directly contribute to the pathological features of these diseases (Bieber, 2008; Yamamoto, 2009) . In atopic dermatitis and scleroderma, molecules such as thymic stromal lymphopoietin (TSLP), which can be a product of keratinocytes, have been suggested to be central to disease development, contributing to a Th2-dominant environment that involves one or several cytokines such as IL-4, IL-13, TNF, and TGF-β (Yoo et al., 2005; Ziegler and Artis, 2010; Usategui et al., 2013) . Through the activity of these molecules (and likely other inflammatory molecules), tissue-remodeling proteins such as collagen and periostin are overproduced, and epidermal hyperplasia is further promoted from the deregulated inflammatory signals received by keratinocytes.In particular, data suggest that the matricellular protein periostin is not only a feature of Type 2 skin inflammatory disease but also plays an essential role in the development of disease Shiraishi et al., 2012; Yang et al., 2012; Taniguchi et al., 2014) . It is primarily expressed by keratinocytes and fibroblasts in the skin, and it has been suggested to have several roles, such as controlling localization of inflammatory infiltrates, including dermal fibroblasts, and contributing to collagen production (Takayama et al., 2006; Sidhu et al., 2010; Ontsuka et al., 2012; Shiraishi et al., 2012; Taniguchi et al., 2014) . In line with these activities, mice deficient in periostin are highly resistant to developing skin disease in models of atopic dermatitis and scleroderma Yang et al., 2012) . Moreover, periostin can also contribute to the speed of wound repair (Nishiyama et al., 2011; Ontsuka et al., 2012) , further emphasizing its importance in the skin. Periostin is currently being used as a clinical marker of type 2 allergic inflammatory disease (Parulekar et al., 2014) , and because IL-13 has been found to induce expression of periostin, it has been proposed that patients that highly express this protein will be responsive to therapies aimed at blocking IL-13 (Parulekar et al., dermatitis is often associated with an allergic reaction characterized by excessive type 2 responses leading to epidermal acanthosis, hyperkeratosis, and dermal inflammation. Although factors like IL-4, IL-13, and thymic stromal lymphopoietin (tSLP) are thought to be instrumental for the development of this type of skin disorder, other cytokines may be critical. Here, we show that the tumor necrosis factor (tnF) superfamily protein LIG Ht (homologous to lymphotoxin, exhibits inducible expression, and competes with HSV glycoprotein d for binding to HVEM, a receptor expressed on t lymphocytes) is required for experimental atopic dermatitis, and LIG Ht directly controls keratinocyte hyperplasia, and production of periostin, a matricellular protein that contributes to the clinical features of atopic dermatitis as well as other skin diseases such as scleroderma. Mice with a conditional deletion of the LIG Ht receptor HVEM (herpesvirus entry mediator) in keratinocytes phenocopied LIG Ht-deficient mice in exhibiting reduced epidermal thickening and dermal collagen deposition in a model of atopic dermatitis driven by house dust mite allergen. LIG Ht signaling through HVEM in human epidermal keratinocytes directly induced proliferation and periostin expression, and both keratinocyte-specific deletion of HVEM or antibody blocking of LIG Ht-HVEM interactions after disease onset prevented expression of periostin and limited atopic dermatitis symptoms. developing reagents that neutralize LIG Ht-HVEM signaling might be useful for therapeutic intervention in skin diseases where periostin is a central feature. (Herro et al., 2015) . LIG HT is primarily a T cell-derived cytokine, but other CD45 + hematopoietic cells such as neutrophils may also be a source, and LIG HT binds to two receptors: HVEM (TNF RSF14) and LTβR (TNF RSF3; Mauri et al., 1998; Scheu et al., 2002; Steinberg et al., 2009) . Whether LIG HT signaling contributes to other types of skin inflammatory disease, such as atopic dermatitis, is unknown, and it is not clear which are the essential cell types that respond to LIG HT. Here, we show that neutralization of LIG HT-HVEM interactions, caused by a deficiency in LIG HT or therapeutic blocking of HVEM signaling, strongly reduced allergen-induced atopic dermatitis in mice. Furthermore, we demonstrate that HVEM expression in keratinocytes is critical for atopic dermatitis and that LIG HT signaling through HVEM specifically controlled keratinocyte hyperplasia and the expression of periostin.
LIG HT-HVEM signaling in keratinocytes controls development of dermatitis
rESuLtS And dIScuSSIon LIG Ht deficiency limits house dust mite (HdM)-induced atopic dermatitis To test whether LIG HT controls the development of atopic dermatitis, we used a murine model (as previously described; Kawakami et al., 2007) induced by epicutaneous sensitization with HDM allergen combined with staphylococcal enterotoxin B, an exacerbating factor for human atopic dermatitis. Strikingly, LIG HT-deficient mice displayed minimal clinical symptoms characteristic of atopic dermatitis, including skin eruption, bleeding, redness, and scaling ( Fig. 1 a) ; weak epidermal hyperplasia; and reduced dermal thickening, with less collagen deposited particularly in the adipose layers (Fig. 1 b) . Additionally, all primary features of type 2 responses were lower in LIG HT-deficient mice, including TSLP and the Th2 cytokines, IL-4, IL-5, and IL-13 (Fig. 1 c) . Moreover, TGF-β, which can contribute to collagen production, and periostin, which is deposited in the dermis and may also aid collagen expression among other activities, were almost absent in the skin of mice lacking LIG HT (Fig. 1 c) . Lastly, overall inflammatory infiltrates were reduced in skin biopsy specimens from LIG HT-deficient hosts, with a trend toward lowered numbers of all cell types analyzed (Fig. 1 d) . Thus, a genetic deficiency in LIG HT protected mice from developing allergen-driven atopic dermatitis, extending our prior finding that LIG HT was instrumental in the development of scleroderma-like skin disease induced by bleomycin.
HVEM-specific deletion in keratinocytes reduces atopic dermatitis
We previously found that both HVEM and LTβR are expressed in keratinocytes (Herro et al., 2015) . To understand the importance of HVEM in these cells, we created conditional knockout mice in which HVEM was specifically deleted (K14-cre HVEM flox/flox ). HVEM is expressed in many cells, including hematopoietic and nonhematopoietic cells. Showing these mice were not globally deficient in HVEM, flow analysis revealed a normal expression pattern of this molecule in the majority of splenic CD45 + and CD45 − cells (not depicted) and normal expression of HVEM in skin fibroblasts, with a specific lack of expression in keratinocytes (Fig. S1 ). Importantly, mice lacking HVEM only in their keratinocytes to a large extent mimicked mice deficient in LIG HT and exhibited resistance to development of atopic dermatitis. Clinical atopic dermatitis symptoms (skin eruption, bleeding, redness, and scaling) were strongly reduced ( Fig. 2 a) , and minimal epidermal and dermal thickening was seen, along with weak deposition of collagen ( Fig. 2 b) and generally poor expression of features of Th2 immunity (Fig. 2 c) . Moreover, mice with a lack of HVEM in keratinocytes phenocopied LIG HT-deficient mice in exhibiting decreased expression of skin TGF-β and dermal periostin (Fig. 2 c) . Interestingly, skin biopsy specimens still revealed significant infiltration of T cells, macrophages, and dendritic cells (Fig. 2 d) , differing from the results with LIG HT-deficient mice (Fig. 1) . Given that ILC2 have been proposed to contribute to atopic dermatitis (Salimi et al., 2013) , and LIG HT might be active on ILC2 as these cells can express HVEM, it is possible that this may explain the difference in inflammatory infiltrates seen between mice lacking LIG HT and those lacking HVEM only in keratinocytes.
LIG Ht-HVEM signaling promotes hyperplasia and periostin expression in keratinocytes
To understand what might be the main activity of HVEM in keratinocytes, we first assessed the action of LIG HT in vitro on normal human epidermal keratinocytes. There were two primary effects that we hypothesized could explain the dramatic effect on atopic dermatitis symptoms when HVEM could not be expressed in these cells. First, LIG HT-HVEM signaling might have regulated division of keratinocytes, driving epidermal hyperplasia. Indeed, in vitro, LIG HT promoted proliferation of keratinocytes, and this was completely prevented by siRNA knockdown of HVEM (Fig. 3 a) .
Second, because both TSLP and periostin have been shown to play a strong role in development of skin inflammation in HDM-driven models Ando et al., 2014) , HVEM signals might have directly controlled the production of either or both proteins. We previously showed in vitro with human keratinocytes that LIG HT could up-regulate TSLP expression (Herro et al., 2015) , but TSLP expression was not affected by siRNA knockdown of HVEM in keratinocytes (Fig. 3 b) . Interestingly, differing from the in vitro results, TSLP was reduced in vivo in the skin in the HVEM conditional knockout animals (Fig. 2) . The latter may then have been a consequence of the lack of HVEM signaling preventing the hyperplasia of keratinocytes necessary for increased TSLP to be expressed.
Most significantly, we found that LIG HT also strongly induced periostin production in keratinocytes at both the mRNA and protein levels and that knockdown of HVEM completely prevented LIG HT activity in this regard (Fig. 3 b) . Previous studies have shown that periostin is highly expressed in the skin of patients with atopic dermatitis and scleroderma (Zhou et al., 2010; Yang et al., 2012) , but exactly how it contributes to tissue inflammation is not clear. Periostin has been described to possess several activities, including binding to extracellular matrix proteins like collagen that could enhance structural rigidity in tissues; binding to several αV integrins (β1/β3/β5) and inducing chemokine production that combined could facilitate localization of T cells, mast cells, and eosinophils with epithelial cells such as keratinocytes; and synergizing with TGF-β to enhance epithelial-mesenchymal transition and collagen deposition that could contribute to tissue remodeling.
To further the conclusion that LIG HT-HVEM interaction is a primary regulator of periostin production by keratinocytes, we treated naive mice subcutaneously with recombinant LIG HT (rLIG HT) given on 2 successive days. Periostin expression was strongly up-regulated in the epidermis and dermis at the transcript and protein levels (Fig. 3 c) at a magnitude only marginally lower than seen in animals epicutaneously primed with house dust mite allergen (see Fig. 1 ). Moreover, mice lacking HVEM in their keratinocytes did not express significant amounts of skin periostin when injected with rLIG HT (Fig. 3 d) . This further illustrates the role of LIG HT signaling through HVEM in these cells and suggests that LIG HT is a novel mediator of periostin production.
As well as keratinocytes/epithelial cells, periostin is a product of fibroblasts and has been primarily thought to be controlled by IL-13 and TGF-β based on studies showing that either cytokine can induce this protein in vitro in these cell types (Takayama et al., 2006; Sidhu et al., 2010; All results representative of (or from) four experiments. Bars, 200 µm. *, P < 0.05; **, P < 0.1; ****, P < 0.001. All statistical data were generated using the Mann-Whitney test.
et al., 2010). It was then a possibility that LIG HT-HVEM signaling might have up-regulated periostin indirectly via these cytokines. However, IL-13 is not a known product of keratinocytes, and blocking this cytokine or TGF-β, that can be produced by keratinocytes, had no effect on LIG HT induction of periostin in vitro (Fig. S2 a) . Importantly, we also found that LIG HT was as effective as IL-13 in driving periostin expression, but interestingly no additive or synergistic activity was seen when LIG HT was combined with IL-13 (Fig. S2 b) . This implies that both cytokines may target the same intracellular pathway that leads to transcription of the periostin gene. We also injected rLIG HT into the skin of IL-4Rα-deficient mice, and found the overall skin reaction was strongly reduced, although not completely, with still some evidence of epidermal thickening and some periostin (Fig. S2 c) . At present, it is not clear how to interpret this result. Given that keratinocyte-specific deletion of HVEM (Figs. 2 and 3 d ) results in weak periostin expression with rLIG HT or allergen exposure, the data with IL-4Rα −/− mice might suggest that IL-13 does synergize with LIG HT in vivo. An alternative possibility is that there is cooperation between HVEM and IL-4Rα that might be independent of IL-13 or IL-4. Further studies will be required to understand these results. Nevertheless, it is likely that LIG HT acts together with both IL-13 and TGF-β in vivo.
Another question for future studies is whether LIG HT is a primary regulator of periostin production in dermal fibroblasts. These cells express both HVEM and LTβR, and preliminary experiments in vitro show that LIG HT can up-regulate periostin expression (not depicted). Therefore, it will be of interest to determine whether fibroblast-specific deletion of HVEM additionally impacts development of atopic dermatitis.
therapeutic blocking of LIG Ht-HVEM interactions suppresses atopic dermatitis
To extend our results, we lastly assessed whether blocking LIG HT-HVEM interactions therapeutically with an anti-HVEM antibody (which neutralizes LIG HT-HVEM, but not LIG HT-LTβR) might reduce allergen-induced atopic dermatitis symptoms and periostin expression. Because we observed full-onset atopic dermatitis by day 7, we treated mice previously sensitized with HDM at this time, with the anti- body given every other day until the end of the experiment (Fig. 4) . Importantly, atopic dermatitis clinical scores were significantly abrogated in anti-HVEM treated mice (Fig. 4 a) , along with a strong reduction in epidermal thickening and a moderate albeit significant decrease in dermal thickness (Fig. 4 b) . Most significantly, periostin expression in the dermis was almost absent after blocking HVEM activity, and less epidermal TSLP expression was observed (Fig. 4 c) . Inflammatory immune infiltrates were largely unaffected, and there were variable effects on Th2 cytokines and TGF-β (Fig. S3) . In summary, our results reveal a novel role for LIG HT-HVEM activity in keratinocytes that is essential for dermatitis in a model of eczema and show that blocking LIG HT-HVEM interactions after disease onset suppresses symptoms of skin inflammatory disease. HVEM is emerging as an important regulator of immune and inflammatory responses, acting in a variety of sites and different cell types, including lymphocytes, myeloid cells, and epithelial cells, but this is the first study that it directly controls immune reactions in the skin and the first showing that it is essential in keratinocytes in vivo. We further delineate a new pathway dependent on LIG HT-HVEM that controls periostin expression in the skin.
Although our studies highlight the role of HVEM in atopic dermatitis, this does not rule out a contribution of LTβR, the other receptor for LIG HT. We knocked down LTβR in human keratinocytes with siRNA and found a significant reduction in proliferation similar to knockdown of HVEM and a reduction in TSLP, but we observed no change in periostin expression (unpublished data). Together with our previous data in a scleroderma model, where blocking LTβR significantly reduced several aspects of skin inflammation (Herro et al., 2015) , it is therefore likely that LTβR is also involved in the pathogenesis of atopic dermatitis. However, future studies with specific deletion of this receptor in vivo will be required to understand its overall role in keratinocytes. Importantly, human studies have found that LIG HT is up-regulated in the serum of atopic dermatitis patients (Kotani et al., 2012; Morimura et al., 2012) , suggesting it could be highly active in human disease. Interestingly, polymorphisms linked to decoy receptor 3, a soluble binding partner and presumed antagonist of FasL, TL1A, and LIG HT, also associate with susceptibility to atopic dermatitis (Sun et al., 2011; Ellinghaus et al., 2013) , and decoy receptor 3 is up-regulated in human atopic dermatitis samples (Chen et al., 2004; Ellinghaus et al., 2013) . The significance of these latter observations is not clear, but the polymorphisms and enhanced expression could lead to defective function of this protein, and subsequently, a bias in the balance between FasL, TL1A, and LIG HT may exist, which might further augment the action of LIG HT in the skin. Together with our results, these findings suggest that reagents that either target LIG HT-HVEM interactions alone or LIG HT interactions with both of its receptors may be beneficial for therapies aiming to halt and potentially abrogate atopic dermatitis in humans.
MAtErIALS And MEtHodS
Mice 6-8-wk-old male WT, LIG HT −/− (Scheu et al., 2002) , and HVEM flox/flox mice crossed to K14-cre mice (Jackson Labs) were bred in-house on the C57BL/6 background. HVEM fl/fl mice were generated at the La Jolla Institute. A frt site-flanked LacZ reporter cassette was inserted into intron 2 of the Tnfrsf14 (HVEM) gene and a variant frt site (F3)-flanked Neo r cassette, for drug selection, was inserted into intron 6 of the Tnfrsf14 gene by recombineering. Germline transmitted Tnfrsf14 flox-neo/flox-neo mice were crossed with mice expressing the FLPe variant of the Saccharomyces cerevisiae FLP1 recombinase mice that deleted the LacZ reporter and the Neo cassette to generate HVEM flox/flox mice. In some experiments, WT BALB/c and IL-4R alpha-deficient mice (Jackson Labs) were used. All experiments were in compliance with the regulations of the La Jolla Institute for Allergy and Immunology Animal Care Committee.
Skin inflammation protocols
Atopic dermatitis-like disease was induced with two cycles of epicutaneous sensitization with HDM extract (10 µg/mouse; Greer Labs) and Staphylococcal enterotoxin B (SEB; 500 ng/ mouse; Toxin Technology) applied directly on the shaved and abraded (using a Dremel for 10 s) back of mice at days 0 and 8, before sacrificing the mice at day 14. After the first and second epicutaneous application of the allergen, the backs of the mice were covered with a gauze pad for 3 d, and then this was removed for 4 d to allow mice to scratch. Clinical symptoms were evident at day 4 and peaked around day 7, with the disease fully established and persisting throughout the second cycle. Clinical symptoms were scored for skin eruption, scaling, bleeding, and redness on a scale from 0 to 3 each, with a cumulative maximum of 12. For neutralization of LIG HT-HVEM interactions, mice were administered 200 µg anti-HVEM mAb (LH1; Anand et al., 2006) given i.v. on day 7 1 d before the second cycle of epicutaneous sensitization with HDM/SEB and every other day i.p. until the end of the experiment.
collagen, skin thickness, and H&E measurements Formalin (4% in PBS)-fixed skin sections were stained with Masson's trichrome blue to evaluate collagen, and H&E to evaluate inflammation. An image analysis system and software (Image-Pro Plus; Media Cybernetics) were used to quantitate epidermal and dermal thickening.
Immunohistochemical staining Skin samples were deparaffinized by sequential placement in xylene and ethanol. Sections were treated with Fc block in 10% donkey serum (in PBS) and stained with (1) rabbit polyclonal antibody to periostin (clone ab14041; Abcam) at 1:200 concentration followed by Rhodamine Red-X AffiniPure donkey anti-rabbit (711295152; Jackson ImmunoResearch) at 1:500 or (2) goat polyclonal antibody to TSLP (clone L18; Santa Cruz Biotechnology) at 1:200 followed by donkey anti-goat IgG-FITC (sc-2024; Santa Cruz Biotechnology) at 1:500. Slides were read on a Nikon 80i microscope and analyzed by LSM-Image software.
Analysis of skin immune cell infiltrates
Skin, including both dermis and epidermis, was minced in the presence of trypsin/dispase, and cellular infiltration was assessed by flow in single-cell suspensions using CD45.2-BV711 (clone 104; BD), CD3e-BV650 (clone 145-2C11; BD), Mac3-Alexa Fluor 647 (clone M4/84; BioLegend), Ly6-G/ Ly6-G-Alexa Fluor 700 (Gr-1, clone RB6-8C5; BioLegend), SiglecF-PE-CF594 (clone E50-2440; BD), CD11b-BB515 (clone M1/70; BD), and CD11c-Brilliant Violet 785 (clone N418; BioLegend 
real-time quantitative Pcr
Total RNA was isolated using TRIzol (Invitrogen) and RNeasy Fibrous Tissue mini kit (74704; Qiagen). Single-strand cDNA was prepared by reverse transcribing 5 µg total RNA using the Transcriptor First Strand cDNA kit (Roche). Samples were amplified in IQ SYRB Green Supermix (Bio-Rad Laboratories) using the following primer pairs: TGF-β forward, 5′-CCC TAT ATT TGG AGC CTG GA-3′; reverse, 5′-GGA AGC TTC GGG ATT TAT GG-3′; huTSLP forward, 5′-TAT GAG TGG GAC CAA AAG TAC CG-3′; reverse, 5′-GGG ATT GAA GGT TAG GCT CTGG-3′; muPeriostin forward, 5′-CCC TCC AGC AAA TTC TGG GCA CCA-3′; reverse, 5′-GAG ACT CAC GTT TTC TTC CCG CAG A-3′; huPeriostin forward, 5′-GAC TCA AGA TGA TTC CCT TT-3′; reverse, 5′-GGT GCA AAG TAA GTG AAGG-3′; mIL13 forward, 5′-CTT GCC TTG GTG GTC TCG-3′; reverse, 5′-CGT TGC ACA GGG GAG TCT-3′; mIL-4 forward, 5′-AGA TCA TCG  GCA TTT TGA ACG-3′; reverse, 5′-TTT GGC ACA TCC  ATC TCCG-3′; mIL-5 forward, 5′-CGC TCA CCG AGC  TCT GTTG-3′; reverse, 5′-CCA ATG CAT AGC TGG TGA  TTT TT-3′ ; and mCollagen forward, 5′-GAG CCC TCG CTT CCG TAC TC-3′; reverse, 5′-TGT TCC CTA CTC AGC CGT CTGT-3′. All samples were run in triplicate, and the mean values were used for quantification. Data are expression relative to ribosomal protein L32 or GAP DH.
Stimulation of keratinocytes and transfection of sirnA Human epidermal keratinocytes from neonates (HEK) or mouse epidermal keratinocytes (PAM212 cell line) were stimulated with 20 ng/ml recombinant human LIG HT (664-LI/CF; R&D), mouse LIG HT (1794-LT-025/CF; R&D), or mouse IL-13 (413-ML-005; R&D) for 72 h in Epilife media (Life Technologies). In some cases, 30 µg/ml anti-TGF-β mAb (1D11; BioXCell) or anti-IL-13 (MAB413-SP; R&D) or isotype control were added into culture. Periostin was measured by immunostaining using anti-hPeriostin mAb (clone ABT292; Millipore) and quantitative PCR analyses. ON-TAR GETplus siRNAs were purchased from Dharmacon. A 5-25 nM concentration range of control scrambled or HVEM siRNA was transfected into HEK cells using HiPerFect transfection reagent (Qiagen). Efficiency of HVEM knockdown was monitored over time by both mRNA and surface protein levels and was stable during the 24-to 72-h culture period. HVEM was visualized using anti-HVEM (BioLegend).
Statistical analyses
Statistical analysis was performed using GraphPad Prism software. A nonparametric Mann-Whitney test was used where indicated. A p-value <0.05 was considered statistically significant.
online supplemental material Fig. S1 shows HVEM expression in skin cells from K14-cre HVEM fl/fl mice. Fig. S2 shows LIG HT regulation of periostin expression independently of IL-13 and TGF-β. Fig. S3 shows cellular infiltration and Th2 cytokines in WT mice sensitized epicutaneously with HDM/SEB and treated with anti-HVEM or IgG.
